# Extensive-stage small-cell lung cancer

Source: https://onco.cc/cancers/extensive-stage-sclc/  
OnCo record `extensive-stage-sclc` (Cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Small-cell lung cancer that has spread responds fast to chemotherapy but almost always returns within a year. Adding an immunotherapy antibody to first-line chemotherapy helps a minority live for years, and the T-cell engager tarlatamab, which points immune cells at the DLL3 protein on the cancer, has for the first time lengthened life after relapse.

## Summary

Extensive-stage small-cell lung cancer has been treated with platinum plus etoposide since the 1980s, with response rates of 60 to 70 percent but relapse within months, and thirty years of trials of added drugs, maintenance and dose intensity failed. IMpower133 (2018) was the first success: adding atezolizumab to carboplatin-etoposide lengthened median overall survival from 10.3 to 12.3 months (hazard ratio 0.70), and CASPIAN (2019) did the same with durvalumab (13.0 versus 10.3 months, hazard ratio 0.73); both were approved in 2019 and 2020 and a long tail of about 15 percent of patients alive at three years appeared. Chinese trials followed with serplulimab (ASTRUM-005, 15.4 versus 10.9 months, hazard ratio 0.63), adebrelimab and benmelstobart. IMforte (2025) then showed that adding lurbinectedin to atezolizumab maintenance after induction extended survival from 10.6 to 13.2 months (hazard ratio 0.73), approved in October 2025.

Second-line treatment was topotecan, with response rates around 20 percent, until lurbinectedin received accelerated approval in 2020 on a 35 percent response rate. Tarlatamab, a bispecific T-cell engager that binds DLL3 on small-cell cells and CD3 on T cells, produced a 40 percent response rate in DeLLphi-301 (2023) with cytokine release syndrome in about half, mostly mild, and received accelerated approval in May 2024; DeLLphi-304 (2025) then showed it lengthened median overall survival to 13.6 months against 8.3 months with chemotherapy (hazard ratio 0.60), the first randomised survival gain after relapse in this disease, and it is now the standard second-line treatment. The B7-H3 antibody-drug conjugate ifinatamab deruxtecan (IDeate-Lung02) and further DLL3 engagers are in phase 3.

Radiotherapy still has roles: prophylactic cranial irradiation improved survival when brain imaging was not routine (Slotman 2007) but not in the Japanese trial with MRI surveillance (Takahashi 2017), so MRI surveillance is increasingly preferred, and thoracic consolidation radiotherapy helps patients with residual chest disease. Open questions are why only a minority benefit durably from immunotherapy, whether the transcription factor subtypes (ASCL1, NEUROD1, POU2F3, inflamed) can direct treatment, and how to move tarlatamab and other DLL3 agents into first line.

## Fields

- Kind: Cancer
- Last checked: 2026-09-17
- Also known as: ES-SCLC; Extensive-disease small-cell lung cancer; Metastatic small-cell lung cancer; Stage IV small-cell lung cancer
- Tags: subtype-page; lung
- Group: lung
- Burden: About 70 percent of small-cell lung cancers are extensive stage at diagnosis, spread beyond one side of the chest, most often to liver, bone, brain and adrenal glands; median survival was about 10 months with chemotherapy alone and is now 12 to 15 months with chemoimmunotherapy, with about one in eight patients alive at three years.
- Subtypes: Extensive-stage small-cell lung cancer, first line (platinum-etoposide plus atezolizumab or durvalumab); Extensive-stage small-cell disease with brain metastases at diagnosis; Relapsed small-cell lung cancer, platinum-sensitive (relapse more than 90 days after chemotherapy); Relapsed small-cell lung cancer, platinum-resistant or refractory; Small-cell lung cancer transformed from EGFR-mutated adenocarcinoma; Neuroendocrine subtypes SCLC-A, SCLC-N, SCLC-P and SCLC-I (research)
- Biomarkers: Stage by PET-CT and brain MRI; Platinum-free interval at relapse (sensitive versus resistant); DLL3 expression (nearly universal; not required for tarlatamab); B7-H3 (ifinatamab deruxtecan trials); Transcription factor subtype and SLFN11 (research); PD-L1 and tumour mutational burden (not predictive in small-cell disease)

## Sections of this record

The page is a hub with ten sections in reading order; large sections have their own page. The same plan as JSON: https://onco.cc/api/v1/cancers/extensive-stage-sclc/sections.json

- Overview (on the hub): The TL;DR, the family this cancer belongs to, the organ, who gets it and what the state of the art is. https://onco.cc/cancers/extensive-stage-sclc/#overview [4 state-of-the-art points]
- Types and stages (on the hub): Anatomy, the subtypes and how they differ, how it is staged, and where advanced disease spreads. https://onco.cc/cancers/extensive-stage-sclc/#what-it-is [6 subtypes]
- Symptoms and diagnosis (on the hub): How this cancer shows itself, how the diagnosis is confirmed, and the biomarkers clinicians test for. https://onco.cc/cancers/extensive-stage-sclc/#finding-it [6 biomarkers]
- Treatment (on the hub): The standard of care by setting, the medicines, surgery and radiotherapy named in it, and the regimens behind them. https://onco.cc/cancers/extensive-stage-sclc/#treating-it [4 settings, 4 decisions with options]
- Trials and papers (own page): Trials recruiting now, the landmark trials, the trials held by this cancer's subtypes, the key papers and what they mean, the latest literature, and the milestones year by year. https://onco.cc/cancers/extensive-stage-sclc/evidence/ [81 trials, 4 key papers, 10 milestones]
- Biology and targets (on the hub): The molecular landscape: the targets and how often each appears, the pathways, the mechanics stages and the preclinical models. https://onco.cc/cancers/extensive-stage-sclc/#science [8 targets, 4 pathways]
- Countries and centres (own page): Cases by country, the UK and NHS pathway and other country lenses, the expert centres with trials on record, and the centres named on this cancer's subtypes. https://onco.cc/cancers/extensive-stage-sclc/where-you-are/ [2 centres, 34 UK centres]
- Decisions and support (on the hub): The decisions you may face, the aids that walk through them, the warnings on record, the first sixty days and the questions to ask. https://onco.cc/cancers/extensive-stage-sclc/#living-with-it [18 questions, 6 red cards]
- Pipeline and open problems (own page): Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record. https://onco.cc/cancers/extensive-stage-sclc/coming/ [15 medicines, 80 trials, 3 ideas, 4 open problems]
- Data (own page): Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked. https://onco.cc/cancers/extensive-stage-sclc/data/ [168 connected records]

## Standard of care

- First line: Four cycles of carboplatin or cisplatin plus etoposide with atezolizumab (IMpower133) or durvalumab (CASPIAN), then maintenance immunotherapy until progression; lurbinectedin added to atezolizumab maintenance (IMforte); serplulimab, adebrelimab or benmelstobart in China. ([Platinum + etoposide (EP / CE)](https://onco.cc/drugs/platinum-etoposide/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Etoposide](https://onco.cc/drugs/etoposide/), [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [IMpower133](https://onco.cc/trials/impower133/), [Durvalumab](https://onco.cc/drugs/durvalumab/), [CASPIAN](https://onco.cc/trials/caspian/), [Lurbinectedin](https://onco.cc/drugs/lurbinectedin/), [IMforte](https://onco.cc/trials/imforte/), [Serplulimab](https://onco.cc/drugs/serplulimab/), [ASTRUM-005](https://onco.cc/trials/astrum-005/), [Adebrelimab](https://onco.cc/drugs/adebrelimab/), [Benmelstobart](https://onco.cc/drugs/benmelstobart/), [Maintenance therapy](https://onco.cc/terms/maintenance-therapy/))
- Second line: Tarlatamab (DeLLphi-304) with inpatient monitoring for cytokine release syndrome during the first doses; lurbinectedin or topotecan as alternatives; platinum-etoposide rechallenge if relapse is more than six months after first line. ([Tarlatamab](https://onco.cc/drugs/tarlatamab/), [DeLLphi-304](https://onco.cc/trials/dellphi-304/), [T-cell engagers (bispecific)](https://onco.cc/technologies/t-cell-engager/), [Cytokine release syndrome (CRS)](https://onco.cc/terms/crs/), [ICANS (neurotoxicity)](https://onco.cc/terms/icans/), [Step-up dosing (T-cell engagers)](https://onco.cc/terms/step-up-dosing/), [Lurbinectedin](https://onco.cc/drugs/lurbinectedin/), [Topotecan](https://onco.cc/drugs/topotecan/), [Platinum + etoposide (EP / CE)](https://onco.cc/drugs/platinum-etoposide/))
- Brain: MRI surveillance every three months or prophylactic cranial irradiation after response to first-line treatment; whole-brain or stereotactic radiotherapy for metastases. ([Prophylactic cranial irradiation vs MRI surveillance](https://onco.cc/technologies/prophylactic-cranial-irradiation/), [Prophylactic cranial irradiation (PCI)](https://onco.cc/terms/pci-term/), [EORTC 08993 (Slotman): prophylactic cranial irradiation in extensive-stage small-cell lung cancer](https://onco.cc/trials/slotman-pci-es-sclc/), [Takahashi trial: prophylactic cranial irradiation with MRI surveillance in extensive-stage small-cell lung cancer](https://onco.cc/trials/takahashi-pci/), [MRI](https://onco.cc/technologies/mri/), [Whole-brain radiotherapy (WBRT)](https://onco.cc/terms/wbrt/), [Stereotactic radiosurgery (Gamma Knife, CyberKnife, linac SRS)](https://onco.cc/technologies/radiosurgery-srs/))
- Thoracic consolidation: Consolidative thoracic radiotherapy (30 Gy in 10 fractions) for patients with residual chest disease after chemotherapy. ([IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/), [Hypofractionated radiotherapy](https://onco.cc/technologies/hypofractionated-radiotherapy/), [Consolidation therapy](https://onco.cc/terms/consolidation-therapy/))

## State of the art

- Chemoimmunotherapy first line (IMpower133, CASPIAN) with a tail of about 15 percent alive at three years.
- Tarlatamab second line: median survival 13.6 versus 8.3 months against chemotherapy in DeLLphi-304, the first randomised gain after relapse.
- Lurbinectedin plus atezolizumab maintenance (IMforte) approved in 2025.
- B7-H3 antibody-drug conjugates and further DLL3 engagers in phase 3; subtype-directed therapy in research.

## Open problems

- No biomarker identifies the minority who gain long-term benefit from immunotherapy; PD-L1 and mutational burden do not work in small-cell disease.
- Tarlatamab needs inpatient monitoring for cytokine release syndrome, which limits access outside specialist centres.
- Whether the transcription factor subtypes can direct treatment is unproven.
- Brain metastases remain common and prophylactic irradiation trades cognition for a benefit that is uncertain with MRI surveillance.

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Small-cell_carcinoma
- Wikipedia: https://en.wikipedia.org/wiki/Small-cell_carcinoma
- NCCN Guidelines: Small Cell Lung Cancer: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1462

## Connected records

- cancers: [Limited-stage small-cell lung cancer](https://onco.cc/cancers/limited-stage-sclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Hypofractionated radiotherapy](https://onco.cc/technologies/hypofractionated-radiotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/), [MRI](https://onco.cc/technologies/mri/), [PET/CT](https://onco.cc/technologies/pet-ct/), [Platinum agents](https://onco.cc/technologies/platinum/), [Prophylactic cranial irradiation vs MRI surveillance](https://onco.cc/technologies/prophylactic-cranial-irradiation/), [Stereotactic radiosurgery (Gamma Knife, CyberKnife, linac SRS)](https://onco.cc/technologies/radiosurgery-srs/), [T-cell engagers (bispecific)](https://onco.cc/technologies/t-cell-engager/), [Targeted alpha therapy](https://onco.cc/technologies/targeted-alpha-therapy/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- targets: [B7-H3](https://onco.cc/targets/b7h3/), [DLL3](https://onco.cc/targets/dll3/), [PD-1](https://onco.cc/targets/pd1/), [PD-L1](https://onco.cc/targets/pdl1/), [TP53](https://onco.cc/targets/tp53/)
- drugs: [Actinium-225 DOTATATE](https://onco.cc/drugs/ryz101/), [Adebrelimab](https://onco.cc/drugs/adebrelimab/), [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Benmelstobart](https://onco.cc/drugs/benmelstobart/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Durvalumab](https://onco.cc/drugs/durvalumab/), [Etoposide](https://onco.cc/drugs/etoposide/), [Ifinatamab deruxtecan](https://onco.cc/drugs/ifinatamab-deruxtecan/), [Lurbinectedin](https://onco.cc/drugs/lurbinectedin/), [Platinum + etoposide (EP / CE)](https://onco.cc/drugs/platinum-etoposide/), [Serplulimab](https://onco.cc/drugs/serplulimab/), [Tarlatamab](https://onco.cc/drugs/tarlatamab/), [Topotecan](https://onco.cc/drugs/topotecan/), [ZL-1310](https://onco.cc/drugs/zl-1310/)
- companies: [Amgen](https://onco.cc/companies/amgen/), [AstraZeneca](https://onco.cc/companies/astrazeneca/), [Daiichi Sankyo](https://onco.cc/companies/daiichi-sankyo/), [Jazz Pharmaceuticals](https://onco.cc/companies/jazz/), [Merck & Co. (MSD)](https://onco.cc/companies/merck/), [PharmaMar](https://onco.cc/companies/pharmamar/), [Roche / Genentech](https://onco.cc/companies/roche-genentech/), [Shanghai Henlius Biotech](https://onco.cc/companies/henlius/)
- institutions: [MD Anderson Cancer Center](https://onco.cc/institutions/md-anderson/), [Memorial Sloan Kettering Cancer Center](https://onco.cc/institutions/mskcc/)
- pathways: [Intrinsic apoptosis (BCL-2 family)](https://onco.cc/pathways/apoptosis-bcl2/), [p53 / RB / cell-cycle checkpoint](https://onco.cc/pathways/p53-cell-cycle/), [PD-1 / PD-L1 immune checkpoint & T-cell activation](https://onco.cc/pathways/pd1-checkpoint/), [Small cell lung cancer (KEGG map)](https://onco.cc/pathways/sclc-signalling/)
- terms: [Brain metastases (intracranial disease)](https://onco.cc/terms/brain-metastases/), [Consolidation therapy](https://onco.cc/terms/consolidation-therapy/), [Cytokine release syndrome (CRS)](https://onco.cc/terms/crs/), [ICANS (neurotoxicity)](https://onco.cc/terms/icans/), [Limited-stage vs extensive-stage (small-cell lung cancer)](https://onco.cc/terms/limited-extensive-stage/), [Maintenance therapy](https://onco.cc/terms/maintenance-therapy/), [Platinum-sensitive / platinum-resistant](https://onco.cc/terms/platinum-sensitivity/), [Prophylactic cranial irradiation (PCI)](https://onco.cc/terms/pci-term/), [Small-cell lung cancer transcription-factor subtypes (SCLC-A, SCLC-N, SCLC-P, SCLC-I) and SLFN11](https://onco.cc/terms/sclc-molecular-subtypes/), [Step-up dosing (T-cell engagers)](https://onco.cc/terms/step-up-dosing/), [Whole-brain radiotherapy (WBRT)](https://onco.cc/terms/wbrt/)
- trials: [A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)](https://onco.cc/trials/nct07227597/), [A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)](https://onco.cc/trials/nct05060016/), [A Phase II Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC](https://onco.cc/trials/nct06177925/), [A Phase II/III Study of IBB0979 in Combination With Topotecan Versus Topotecan in Relapsed Small Cell Lung Cancer](https://onco.cc/trials/nct07076095/), [A Single-arm, Open-label, Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of HLX10 + Chemotherapy in Patients With ES-SCLC](https://onco.cc/trials/nct06812260/), [A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Pa](https://onco.cc/trials/nct07502300/), [A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Sm](https://onco.cc/trials/nct07802821/), [A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small](https://onco.cc/trials/nct07005128/), [A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab](https://onco.cc/trials/nct05142696/), [A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer](https://onco.cc/trials/nct06095505/), [A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung Cancer](https://onco.cc/trials/nct07538271/), [A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer](https://onco.cc/trials/nct05924841/), [A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer](https://onco.cc/trials/nct06437509/), [A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer](https://onco.cc/trials/nct07654400/), [A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-](https://onco.cc/trials/nct06362252/), [A Study of Ivonescimab in First-Line ES-SCLC](https://onco.cc/trials/nct07245446/), [A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC](https://onco.cc/trials/nct07459634/), [A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC](https://onco.cc/trials/nct05844150/), [A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)](https://onco.cc/trials/nct03033511/), [A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer](https://onco.cc/trials/nct07739758/), [A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Ther](https://onco.cc/trials/nct07796100/), [A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)](https://onco.cc/trials/dllevate/), [A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy](https://onco.cc/trials/nct07564401/), [A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus St](https://onco.cc/trials/nct07155174/), [A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensiv](https://onco.cc/trials/nct06780137/), [A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2](https://onco.cc/trials/nct07203053/), [Addition of Thoracic Consolidation Radiotherapy to the Maintenance Immunotherapy for ES-SCLC (STONE-001)](https://onco.cc/trials/nct06719336/), [Adebrelimab + Apatinib in SCLC Maintenance Therapy](https://onco.cc/trials/nct06475209/), [Adebrelimab Combined with Chemotherapy and Thoracic Radiotherapy for First-line Treatment of ES-SCLC](https://onco.cc/trials/nct06672133/), [ASTRUM-005](https://onco.cc/trials/astrum-005/), [Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).](https://onco.cc/trials/nct06663098/), [BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)](https://onco.cc/trials/nct07625644/), [CASPIAN](https://onco.cc/trials/caspian/), [CREST: consolidation thoracic radiotherapy in extensive-stage small-cell lung cancer](https://onco.cc/trials/crest-thoracic-rt/), [DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment](https://onco.cc/trials/nct07472517/), [DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers](https://onco.cc/trials/nct05882058/), [DeLLphi-304](https://onco.cc/trials/dellphi-304/), [DeLLphi-305](https://onco.cc/trials/dellphi-305/), [Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and C](https://onco.cc/trials/nct06698965/), [EORTC 08993 (Slotman): prophylactic cranial irradiation in extensive-stage small-cell lung cancer](https://onco.cc/trials/slotman-pci-es-sclc/), [Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC](https://onco.cc/trials/nct07110103/), [IDeate-Lung02](https://onco.cc/trials/ideate-lung02/), [Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)](https://onco.cc/trials/nct05280470/), [IMforte](https://onco.cc/trials/imforte/), [IMpower133](https://onco.cc/trials/impower133/), [IN10018 Combination Therapy in Treatment-naïve ES-SCLC](https://onco.cc/trials/nct06030258/), [JK-1201I Compared with Topotecan in Patients with Relapsed Extensive Stage Small Cell Lung Cancer](https://onco.cc/trials/nct06581380/), [Lurbinectedin basket trial, small-cell lung cancer cohort](https://onco.cc/trials/lurbinectedin-basket-sclc/), [Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extens](https://onco.cc/trials/nct06419179/), [MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer](https://onco.cc/trials/nct05903092/), [Multicenter, Phase II Randomized Controlled Study of Adebrelimab Combined With Chemotherapy and Concurrent Low-Dose Radiotherapy (LDRT) for the Treatment of Ext](https://onco.cc/trials/nct06610734/), [Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-stage Small Cell Lung Cancer in the Cache](https://onco.cc/trials/nct06961201/), [Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC](https://onco.cc/trials/nct05718323/), [Organoid-guided vs Topotecan Therapy in Relapsed Extensive-Stage Small Cell Lung Cancer](https://onco.cc/trials/nct07106528/), [Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC)](https://onco.cc/trials/nct05623319/), [Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)](https://onco.cc/trials/nct05224141/), [Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)](https://onco.cc/trials/nct07778316/), [Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation](https://onco.cc/trials/nct06110572/), [Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer](https://onco.cc/trials/nct07057791/), [Prophylactic Cranial Irradiation Overview (Auperin meta-analysis)](https://onco.cc/trials/pci-overview-1999/), [Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients](https://onco.cc/trials/nct05703971/), [S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cel](https://onco.cc/trials/nct04155034/), [Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC)](https://onco.cc/trials/nct07501169/), [Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer](https://onco.cc/trials/nct06712355/), [Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)](https://onco.cc/trials/nct04938817/), [Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy](https://onco.cc/trials/nct06449209/), [SNB-101 for Treatment of Extensive Stage Small Cell Lung Cancer](https://onco.cc/trials/nct07391813/), [Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)](https://onco.cc/trials/nct03061812/), [Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer](https://onco.cc/trials/nct04665856/), [Study of AZD2811 + Durvalumab in ES-SCLC](https://onco.cc/trials/nct04745689/), [Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases](https://onco.cc/trials/nct05588388/), [Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer](https://onco.cc/trials/nct05450965/), [Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer](https://onco.cc/trials/nct06801834/), [Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer](https://onco.cc/trials/nct07339059/), [Takahashi trial: prophylactic cranial irradiation with MRI surveillance in extensive-stage small-cell lung cancer](https://onco.cc/trials/takahashi-pci/), [Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer](https://onco.cc/trials/nct07423585/), [Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer](https://onco.cc/trials/nct04919382/), [Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled Study](https://onco.cc/trials/nct07583511/), [To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC](https://onco.cc/trials/nct05468489/), [Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell](https://onco.cc/trials/nct06441344/), [Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer](https://onco.cc/trials/nct04373369/)
- people: [Charles M. Rudin](https://onco.cc/people/charles-rudin/), [Luis Paz-Ares](https://onco.cc/people/luis-paz-ares/), [Martin Reck](https://onco.cc/people/martin-reck/), [Ying Cheng](https://onco.cc/people/cheng-ying/)
- key papers: [DeLLphi-301: tarlatamab, a DLL3-targeting T-cell engager, in previously treated small-cell lung cancer](https://onco.cc/key-papers/paper-dellphi-301-nejm-2023/), [Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN)](https://onco.cc/key-papers/paper-paz-ares-caspian-durvalumab-es-sclc-lancet-2019/), [Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data](https://onco.cc/key-papers/paper-rudin-sclc-molecular-subtypes-nat-rev-cancer-2019/), [Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission](https://onco.cc/key-papers/paper-auperin-prophylactic-cranial-irradiation-sclc-nejm-1999/)
- ideas: [MRI surveillance replaces prophylactic cranial irradiation in SCLC](https://onco.cc/ideas/idea-mri-surveillance-replaces-pci/), [Run small-cell lung cancer as one platform with shared controls and subtype stratification](https://onco.cc/ideas/idea-lung-small-cell-platform-with-shared-controls-and-subtypes/), [Subtype-directed therapy for SCLC (ASCL1 / NEUROD1 / POU2F3 / inflamed)](https://onco.cc/ideas/idea-sclc-subtype-directed/)
- pairings: [Chemo-immunotherapy induction → maintenance intensification (SCLC)](https://onco.cc/pairings/chemo-io-then-maintenance-sclc/), [Sequencing DLL3 engager and B7-H3 ADC in relapsed SCLC](https://onco.cc/pairings/tarlatamab-vs-idxd-sequence/)
- biomarkers: [B7-H3 (CD276) expression](https://onco.cc/biomarkers/b7-h3-expression/), [DLL3 expression](https://onco.cc/biomarkers/dll3-expression/)

---
JSON: https://onco.cc/api/v1/entities/extensive-stage-sclc.json